$14.05
7.11% yesterday
Nasdaq, Nov 15, 09:47 pm CET
ISIN
US45826J1051
Symbol
NTLA
Sector
Industry

Intellia Therapeutics, Inc. Stock price

$13.97
-5.55 28.43% 1M
-12.25 46.72% 6M
-16.52 54.18% YTD
-12.61 47.44% 1Y
-119.57 89.54% 3Y
+0.67 5.04% 5Y
-8.13 36.79% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-1.15 7.61%
ISIN
US45826J1051
Symbol
NTLA
Sector
Industry

Key metrics

Market capitalization $1.42b
Enterprise Value $866.34m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 20.11
P/S ratio (TTM) P/S ratio 33.02
P/B ratio (TTM) P/B ratio 1.48
Revenue growth (TTM) Revenue growth -16.77%
Revenue (TTM) Revenue $43.09m
EBIT (operating result TTM) EBIT $-537.71m
Free Cash Flow (TTM) Free Cash Flow $-363.06m
Cash position $658.11m
EPS (TTM) EPS $-5.45
P/E forward negative
P/S forward 28.13
EV/Sales forward 17.97
Short interest 18.07%
Show more

Is Intellia Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Intellia Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

30 Analysts have issued a Intellia Therapeutics, Inc. forecast:

24x Buy
80%
6x Hold
20%

Analyst Opinions

30 Analysts have issued a Intellia Therapeutics, Inc. forecast:

Buy
80%
Hold
20%

Financial data from Intellia Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
43 43
17% 17%
100%
- Direct Costs 10 10
19% 19%
24%
33 33
24% 24%
76%
- Selling and Administrative Expenses 112 112
9% 9%
260%
- Research and Development Expense 448 448
7% 7%
1,040%
-528 -528
11% 11%
-1,224%
- Depreciation and Amortization 10 10
19% 19%
24%
EBIT (Operating Income) EBIT -538 -538
11% 11%
-1,248%
Net Profit -522 -522
13% 13%
-1,212%

In millions USD.

Don't miss a Thing! We will send you all news about Intellia Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Intellia Therapeutics, Inc. Stock News

Positive
Seeking Alpha
5 days ago
Intellia Therapeutics' NTLA-2002 Phase II results last month were underwhelming, however, management reassured investors on the Q3 earnings call setting the stage for a modest rally. While last month's drop is appropriately discounting NTLA-2002, investors should be encouraged that 3 Phase III trials will be engaged by year-end, representing multiple opportunities for substantial upside. Intell...
Positive
MarketBeat
5 days ago
Comparing and selecting stocks for investment may involve any number of increasingly complex strategies and approaches, but sometimes simpler is better: targeting a stock with significant upside potential at an opportune moment. Certainly, achieving this goal is easier said than done, and there is no guarantee that a company expected to make sizable gains will follow through on that promise.
Neutral
Seeking Alpha
8 days ago
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Lina Li - Senior Director of Investor Relations and Corporate Communications John Leonard - President & Chief Executive Officer David Lebwohl - Chief Medical Officer Laura Sepp-Lorenzino - Executive Vice President & Chief Scientific Officer Ed Dulac - Executive Vice Presi...
More Intellia Therapeutics, Inc. News

Company Profile

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Head office United States
CEO John Leonard
Employees 526
Founded 2014
Website www.intelliatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today